Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

VCVivek CharuAEAsiri EdiriwickremaGMGabriel N. Mannis

Discussion

Loading...

Member takes

Overview

Investigator-initiated trial assesses safety of tagraxofusp and cladribine in patients with acute myeloid leukemia, suggesting improved therapy potential after venetoclax failure.

Key Points

  • Combination of tagraxofusp and cladribine shows potential for improving outcomes in acute myeloid leukemia after venetoclax failure.
  • The trial will evaluate the complete response rate and safety of treatment in relapsed or refractory patients.
  • Investigator-initiated, randomized controlled trial gauging efficacy of therapy for acute myeloid leukemia with dose escalation of cladribine.
  • Study findings may enable better treatment strategies for patients with limited options after initial therapy.

Cite This Study

Charu et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e17fhttps://doi.org/10.1182/blood-2025-8256
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial2025 · 4 citations
  2. 2Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial2025
  3. 3Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome2025 · 2 citations
  4. 4Trial in progress: A pilot study of venetoclax to AUGMENT epigenetic modification and chemotherapy in pediatric and young adult patients with relapsed and refractory Acute Myeloid Leukemia2025 · 1 citations
  5. 5Phase 1b study of HC-7366 alone and in combination with venetoclax and azacitidine in relapsed/refractory Acute Myeloid Leukemia2025 · 1 citations